Supply chain issues shift patient timeline to late 2025
Vicarious Surgical announced slight delays in its Version 1.0 (V1.0) surgical robot timeline, citing material procurement issues. Despite this, shares rose 3.6% following strong Q4 results.
The company now expects first patient treatments by late 2025, with FDA submission pushed to late fiscal 2026 — a 3–6 month delay. Vicarious has since resolved supply issues and continues building inventory and securing ethics approvals for clinical trials.
In Q4, the company posted $14.4M in net losses, beating Wall Street estimates. Full-year cash burn matched guidance at $49.1M, with $50M projected for 2025.
Follow MEDWIRE.AI for the latest in surgical robotics.
